Abstract A system for controlled release, site-specific delivery of therapeutic agents, particularly myocardial agents such as antiarrhythmic agents, comprises a biocompatible polymeric matrix with an incorporated therapeutic agent for direct placement at the epicardium. Advantageously, the dosage form can be fabricated in such a manner as to tailor the release characteristics as required by the nature of the physical condition desired to be treated. In a specific illustrative embodiment, lidocaine, an antiarrhythmic depressant, is incorporated in polyurethane by a unique method which permits drug-loading of the polymeric matrix from about 5% up to 40% by weight, with about 25% to 30% in a preferred embodiment. A novel FeCl3 catalyst causes the polyurethane to polymerize despite the presence of drug in the polymeric matrix mixture.
A method of making a device for controlled release of an antiarrhythmic drug comprising: (a) forming a mixture of about 4 parts lidocaine hydrochloride; 10 parts polyurethane prepolymer, said polyurethane prepolymer comprising about 0.21 parts diisocyanate monomer and about 0.79 parts polyether monomer; and about 0.74 μM FeCl 3 /g polyether monomer; (b) forming the mixture into a desired shape; and (c) curing the formed mixture at a temperature in the range of 50° C. to 60° C. for a period of time ranging from about 24 hours to 3 days.
Claim 2
Independent Claim
91 words
A method of making a device for controlled release of an antiarrhythmic drug comprising: (a) forming a mixture of about 4 parts lidocaine hydrochloride; 10 parts polyurethane prepolymer, said polyurethane prepolymer comprising about 0.21 parts diisocyanate monomer and about 0.79 parts polyether monomer; and about 0.74 μM FeCl 3 /g polyether monomer; (b) forming the mixture into a desired shape; and (c) curing the formed mixture at a temperature in the range of 50° C. to 60° C. for a period of time ranging from about 24 hours to 3 days.